PitchSend

argenx SE Investor Day Presentation Deck

Phase 1 Data Support Path Forward and Potential for Individualized Dosing Schedule in Patients Favorable safety & tolerability profile supports advancing to Phase 2 patient trials Consistent PK/PD profile across IV and SC dosing that may enable infrequent dosing Phase 2 trial in multifocal motor neuropathy (MMN) to start by end of year argenx 61

View entire presentation